557 related articles for article (PubMed ID: 15472417)
1. Memantine: pharmacological properties and clinical uses.
Kumar S
Neurol India; 2004 Sep; 52(3):307-9. PubMed ID: 15472417
[TBL] [Abstract][Full Text] [Related]
2. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia].
Tanović A; Alfaro V
Rev Neurol; 2006 May 16-31; 42(10):607-16. PubMed ID: 16703529
[TBL] [Abstract][Full Text] [Related]
3. Alzheimer's disease and the glutamate NMDA receptor.
Doraiswamy PM
Psychopharmacol Bull; 2003; 37(2):41-9. PubMed ID: 14566213
[TBL] [Abstract][Full Text] [Related]
4. [The clinical relevance of memantine use].
Sobów T
Psychiatr Pol; 2004; 38(2):321-30. PubMed ID: 15307296
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacological therapy in Alzheimer's disease. Current clinical practice in The Netherlands].
Schölzel-Dorenbos CJ;
Tijdschr Gerontol Geriatr; 2005 Jul; 36(3):122-6. PubMed ID: 16078659
[TBL] [Abstract][Full Text] [Related]
6. [Advanced dementia in Alzheimer's disease and memantine].
Alberca R
Rev Neurol; 2005 Feb 1-15; 40(3):173-9. PubMed ID: 15750904
[TBL] [Abstract][Full Text] [Related]
7. Memantine: new preparation. Poor evaluation and uncertain benefit in Alzheimer's disease.
Prescrire Int; 2003 Dec; 12(68):203-5. PubMed ID: 14986682
[TBL] [Abstract][Full Text] [Related]
8. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy.
Hartmann S; Möbius HJ
Int Clin Psychopharmacol; 2003 Mar; 18(2):81-5. PubMed ID: 12598818
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.
Bullock R
Alzheimer Dis Assoc Disord; 2006; 20(1):23-9. PubMed ID: 16493232
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of memantine in the treatment of Alzheimer's disease].
Molinuevo Guix JL; Lladó Plarrumaní A
Neurologia; 2005 Dec; 20(10):686-91. PubMed ID: 16317590
[TBL] [Abstract][Full Text] [Related]
11. Memantine in the treatment of dementia.
Maggiore C; Locatelli L; Grandi FC; Pizzolato G;
Neuroepidemiology; 2007; 28(2):118-9. PubMed ID: 17409774
[No Abstract] [Full Text] [Related]
12. Neuropathologic changes in Alzheimer's disease: potential targets for treatment.
Wenk GL
J Clin Psychiatry; 2006; 67 Suppl 3():3-7; quiz 23. PubMed ID: 16649845
[TBL] [Abstract][Full Text] [Related]
13. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
Tariot PN
J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
[TBL] [Abstract][Full Text] [Related]
14. Memantine for dementia?
Drug Ther Bull; 2003 Oct; 41(10):73-6. PubMed ID: 14593973
[TBL] [Abstract][Full Text] [Related]
15. Memantine in dementia: a review of the current evidence.
Herrmann N; Li A; Lanctôt K
Expert Opin Pharmacother; 2011 Apr; 12(5):787-800. PubMed ID: 21385152
[TBL] [Abstract][Full Text] [Related]
16. [Memantine].
Molinuevo JL
Neurologia; 2003 Jun; 18(5):255-61. PubMed ID: 12768511
[TBL] [Abstract][Full Text] [Related]
17. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP
Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32).
Olin JT; Bhatnagar V; Reyes P; Koumaras B; Meng X; Brannan S
Int J Geriatr Psychiatry; 2010 Apr; 25(4):419-26. PubMed ID: 19670390
[TBL] [Abstract][Full Text] [Related]
19. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease.
Grossberg GT; Pejović V; Miller ML; Graham SM
Dement Geriatr Cogn Disord; 2009; 27(2):164-72. PubMed ID: 19194105
[TBL] [Abstract][Full Text] [Related]
20. Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain.
Enz A; Gentsch C
Neuropharmacology; 2004 Sep; 47(3):408-13. PubMed ID: 15275830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
